No, Rozrolimupab (not "trinbelimab") is NOT the same as RhoGAM
Rozrolimupab is a recombinant human monoclonal IgG1 anti-D antibody, while RhoGAM is a plasma-derived polyclonal anti-D immunoglobulin—they differ fundamentally in their source, manufacturing, and potentially their clinical efficacy.
Key Differences
Source and Manufacturing
RhoGAM: Manufactured from pooled human plasma obtained from Rh-negative donors who have been immunized with Rh-positive red blood cells 1. It contains polyclonal antibodies (multiple different anti-D antibodies from multiple donors).
Recombinant monoclonal anti-D: Produced through cell culture technology (various cell lines including human B-lymphoblastoid, Chinese hamster ovary, or rat YB2/0 cells) 2, 3. It consists of a single cloned antibody.
Clinical Efficacy Considerations
The critical issue is that monoclonal anti-D products have shown variable efficacy compared to plasma-derived RhoGAM 4, 3. This variation stems primarily from differences in:
Fc-glycosylation patterns: The sugar molecules attached to the antibody's Fc region dramatically affect how well it works 3, 5
- Fucosylation levels: RhoGAM typically has ~93% fucosylation of total IgG, but its anti-D component shows reduced fucosylation (47-65%) 5. Lower fucosylation enhances binding to FcγRIIIa receptors, improving red cell clearance 3
- Galactosylation: RhoGAM preparations show 64-82% galactosylation 5, which may provide anti-inflammatory effects
Manufacturing cell line matters: Monoclonal anti-D from different cell lines shows vastly different glycosylation:
Clinical Trial Results
Early monoclonal anti-D products (BRAD-3 and BRAD-5) showed promise in Phase I trials 6, 7:
- Protected volunteers from Rh D immunization
- Demonstrated appropriate half-lives (10.2 days for IgG3, 22.2 days for IgG1) 6
- However, none have yet proven as effective as plasma-derived polyclonal anti-D in clinical trials 4
Current Clinical Practice
RhoGAM remains the standard of care [8-8. The 2024 SMFM guidelines consistently reference RhIg (Rho(D) Immune Globulin) without distinguishing between products, because:
- RhoGAM and equivalent plasma-derived products (WinRho SDF, HyperRHO S/D, Rhophylac) are interchangeable 8
- No recombinant monoclonal anti-D product has received FDA approval for routine Rh prophylaxis
- The proven track record of plasma-derived products shows dramatic reduction in hemolytic disease of the fetus and newborn 8
Important Caveats
- Supply issues: Recent shortages of RhoGAM and WinRho SDF have been reported 8, making development of recombinant alternatives increasingly important
- Future potential: Recombinant products could provide unlimited supply and eliminate blood-borne pathogen concerns 4, 3
- Optimization needed: Future monoclonal products should target <60% fucosylation and >60% galactosylation to match or exceed RhoGAM efficacy 3
In summary: While recombinant monoclonal anti-D antibodies represent a promising future alternative, they are not currently equivalent to or interchangeable with RhoGAM in clinical practice.